Open AccessCharacteristics and Outcomes of People With Gout Hospitalized Due to COVID ‐19: Data From the COVID ‐19 Global Rheumatology Alliance Physician‐Reported Registry
Author(s) -
Jatuworapruk Ka,
Montgomery Anna,
Gianfrancesco Milena,
Conway Richard,
Durcan Laura,
Graef Elizabeth R.,
Jayatilleke Aruni,
Keen Helen,
Kilian Adam,
Young Kristen,
Carmona Loreto,
Cogo Adriana Karina,
DuarteGarcía Alí,
Gossec Laure,
Hasseli Rebecca,
Hyrich Kimme L.,
Langlois Vincent,
LawsonTovey Saskia,
Malcata Armando,
Mateus Elsa F,
Schafer Martin,
Scirè Carlo Alberto,
Sigurdardottir Valgerdur,
Sparks Jeffrey A.,
Strangfeld Anja,
Xavier Ricardo M.,
Bhana Suleman,
GoreMassy Monique,
Hausmann Jonathan,
Liew Jean W.,
Sirotich Emily,
Sufka Paul,
Wallace Zach,
Machado Pedro M.,
Yazdany Jinoos,
Grainger Rebecca,
Robinson Philip C.
Publication year - 2022
Publication title -
acr open rheumatology
Language(s) - English
Resource type - Journals
ISSN - 2578-5745
DOI - 10.1002/acr2.11495
Subject(s) - medicine , comorbidity , cohort , gout , cohort study , diabetes mellitus , endocrinology
Objective To describe people with gout who were diagnosed with coronavirus disease 2019 (COVID‐19) and hospitalized and to characterize their outcomes. Methods Data on patients with gout hospitalized for COVID‐19 between March 12, 2020, and October 25, 2021, were extracted from the COVID‐19 Global Rheumatology Alliance registry. Descriptive statistics were used to describe the demographics, comorbidities, medication exposures, and COVID‐19 outcomes including oxygenation or ventilation support and death. Results One hundred sixty‐three patients with gout who developed COVID‐19 and were hospitalized were included. The mean age was 63 years, and 85% were male. The majority of the group lived in the Western Pacific Region (35%) and North America (18%). Nearly half (46%) had two or more comorbidities, with hypertension (56%), cardiovascular disease (28%), diabetes mellitus (26%), chronic kidney disease (25%), and obesity (23%) being the most common. Glucocorticoids and colchicine were used pre‐COVID‐19 in 11% and 12% of the cohort, respectively. Over two thirds (68%) of the cohort required supplemental oxygen or ventilatory support during hospitalization. COVID‐19‐related death was reported in 16% of the overall cohort, with 73% of deaths documented in people with two or more comorbidities. Conclusion This cohort of people with gout and COVID‐19 who were hospitalized had high frequencies of ventilatory support and death. This suggests that patients with gout who were hospitalized for COVID‐19 may be at risk of poor outcomes, perhaps related to known risk factors for poor outcomes, such as age and presence of comorbidity.